Tafamidis—A Pricey Therapy for a Not-So-Rare Condition-Reference-Cited by-同舟云学术

Tafamidis—A Pricey Therapy for a Not-So-Rare Condition

Published:2020-03-01 Issue:3 Volume:5 Page:247
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Gurwitz Jerry H.¹²,Maurer Mathew S.³

Affiliation:

1. Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Health, and Reliant Medical Group, Worcester

2. Division of Geriatric Medicine, University of Massachusetts Medical School, Worcester

3. Center for Cardiac Amyloidosis, Division of Cardiology, Department of Internal Medicine, Columbia University Irving Medical Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2758314/jamacardiology_gurwitz_2020_vp_190018_1609877379.69638.pdf

Reference7 articles.

1. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.;Maurer;N Engl J Med,2018

2. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.;González-López;Eur Heart J,2015

3. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.;Gillmore;Circulation,2016

4. Novel therapies for an aging population: grappling with price, value, and affordability.;Gurwitz;JAMA,2019

5. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.;Anderson;Circulation,2014

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Diflunisal in Patients with Transthyretin Cardiomyopathy: A Pilot Study;Journal of Clinical Medicine;2024-08-25

2. From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics;American Journal of Health-System Pharmacy;2024-07-04

3. Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system;Scientific Reports;2024-06-13

4. Heart Failure in African American Individuals, Version 2.0;JAMA;2024-06-04

5. Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician;International Journal of Cardiology;2024-05